R&D
Rooted in distinctive platform technology based on strong medicinal chemistry expertise, LCB is a global biotechnology company dedicated to drug discovery and development
Research Area
We focus on developing ADCs, immuno-oncology drugs, and antibiotics by combining our expertise in medicinal chemistry, biology, and immuno-oncology.
ADC
Antibody-Drug Conjugates
ADC is a therapeutic approach in oncology that combines an antibody that selectively targeting tumor cells and a cytotoxic payload, that kills the target cell with a linker that joins together the antibody and the payload.
To create new therapeutic opportunities we are expanding into AIC and ADIC, our novel approach by combining immuno-oncology payloads.
To create new therapeutic opportunities we are expanding into AIC and ADIC, our novel approach by combining immuno-oncology payloads.
NCE
Small molecule-based drug (NCE)
For our next-generation ADC platforms, we are developing new linkers and payloads by leveraging our expertise in medicinal chemistry. This will strengthen the competitive edge of our core business area.
We have also broadening our therapeutic area to immuno-oncology for use in both mono and combination therapies.
We have also broadening our therapeutic area to immuno-oncology for use in both mono and combination therapies.
